Markers of sarcoidosis

Sarcoidosis

Volumn , Issue , 2005, Pages 435-462

  Baughman, Robert P ^a   Costabel, Ulrich ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b RUHRLANDKLINIK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249878010     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (193)

1. Subcommitteeonpulmonary toxicology: Committeeonbiologicmarkers. Biologic markers inpulmonary toxicology. Washington, DC: National academypress, 1989.
2. Lieberman J. Enzymes in sarcoidosis. Angiotensin-converting-enzyme (ACE). Clin Lab Med 1989; 9(4): 745-755.
3. Lieberman J. Elevation of serum angiotensin converting enzyme (ACE) level in sarcoidosis. Am J Med 1975; 59: 365-372.
4. Rohrbach MS, De Remee RA. Serum angiotensin converting enzyme activity in sarcoidosis as measured by a simple radiochemical assay. Am Rev Respir Dis 1979; 119(5): 761-767.
5. Kasahara Y, Ashihara Y. Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 1981; 27(11): 1922-1925.
6. Lieberman J, Zakria F. Effect of captopril and enalapril medication on the serum ACE test for sarcoidosis. Sarcoidosis 1989; 6(2): 118-123.
7. Rohrbach MS, De Remee RA. Age dependence of serum angiotensin-converting enzyme activity. Lancet 1979; 2(8135): 196.
8. Lieberman J, Nosal A, Schlessner A, Sastre-Foken A. Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis 1979; 120(2): 329-335.
9. Lieberman J. The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis. Ann N Y Acad Sci 1976; 278: 488-497.
10. Studdy P, Bird R, James DG. Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders. Lancet 1978; 2: 1331-1334.
11. Gronhagen-Riska C, Selroos O, Wagar G, Fyhrquist F. Angiotensin-converting enzyme. II. Serum activity in early and newly diagnosed sarcoidosis. Scand J Respir Dis 1979; 60(2): 94-101.
12. Loddenkemper R, Kloppenborg A, Schoenfeld N, Grosser H, Costabel U. Clinical findings in 715 patients with newly detected pulmonary sarcoidosis-results of a cooperative study in former West Germany and Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft fur die Therapie von Lungenkrankheitan. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15(2): 178-182.
13. Silverstein E, Friedland J, Kitt M, Lyons HA. Increased serum angiotensin converting enzyme activity in sarcoidosis. Isr J Med Sci 1977; 13(10): 995-1000.
14. Lieberman J, Sastre A. Angiotensin-converting enzyme activity in postmortem human tissues. Lab Invest 1983; 48(6): 711-717.
15. Hinman LM, Stevens C, Matthay RA, Bernard J, Gee L. Angiotensin convertase activities in human alveolar macrophages: effects of cigarette smoking and sarcoidosis. Science 1979; 205(4402): 202-203.
16. Silverstein E, Friedland J, Ackerman T. Elevation of granulomatous lymphnode and serum lysozyme in sarcoidosis and correlation with angiotensinconverting enzyme. Am J Clin Pathol 1977; 68(2): 219-224.
17. Silverstein E, Friedland J, Lyons HA, Gourin A. Markedly elevated angiotensin converting enzyme in lymph nodes containing non-necrotizing granulomas in sarcoidosis. Proc Natl Acad Sci USA 1976; 73(6): 2137-2141.
18. Silverstein E, Pertschuk LP, Friedland J. Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas. Proc Natl Acad Sci USA 1979; 76(12): 6646-6648.
19. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86(4): 1343-1346.
20. Tomita H, Ina Y, Sugiura Y, Sato S, Kawaguchi H, Morishita M, et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med 1997; 156(1): 255-259.
21. Furuya K, Yamaguchi E, Itoh A, Hizawa N, Ohnuma N, Kojima J, et al. Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax 1996; 51(8): 777-780.
22. Takemoto Y, Sakatani M, Takami S, Tachibana T, Higaki J, Ogihara T, et al. Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis [see comments]. Thorax 1998; 53(6): 459-462.
23. Marshall BG, Shaw RJ. Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis. Thorax 1998; 53(6): 439-440.
24. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342(8879): 1073-1075.
25. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359(6396): 641--644.
26. Harden PN, Geddes C, Rowe PA, McIlroy JH, Boulton-Jones M, Rodger RS, et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345(8964): 1540-1542.
27. Maliarik MJ, Rybicki BA, Malvitz E, Sheffer RG, Major M, Popovich J, et al. Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med 1998; 158(5 pt 1): 1566-1570.
28. Rybicki BA, Maliarik MJ, Poisson LM, Iannuzzi MC. Sarcoidosis and granuloma genes: a family-based study in African Americans. Eur Respir J 2004; 24(2): 251-257.
29. McGrath DS, Foley PJ, Petrek M, Izakovicova-Holla L, Kolek V, Veeraraghavan S, et al. Ace gene I/D polymorphism and sarcoidosis pulmonary disease severity. Am J Respir Crit Care Med 2001; 164(2): 197-201.
30. Arbustini E, Grasso M, Leo G, Tinelli C, Fasani R, Diegoli M, et al. Polymorphism of angiotensin-converting enzyme gene in sarcoidosis. Am J Respir Crit Care Med 1996; 153(2): 851-854.
31. Schurmann M, Reichel P, Muller-Myhsok B, Dieringer T, Wurm K, Schlaak M, et al. Angiotensin-converting enzyme (ACE) gene polymorphisms and familial occurrence of sarcoidosis. J Intern Med 2001; 249(1): 77-83.
32. Maier LA, Raynolds MV, Young DA, Barker EA, Newman LS. Angiotensin-1 converting enzyme polymorphisms in chronic beryllium disease. Am J Respir Crit Care Med 1999; 159(4 Pt 1): 1342-1350.
33. Planck A, Eklund A, Yamaguchi E, Grunewald J. Angiotensin-converting enzyme gene polymorphism in relation to HLA-DR in sarcoidosis. J Intern Med 2002; 251(3): 217-222.
34. Pietinalho A, Furuya K, Yamaguchi E, Kawakami Y, Selroos O. The angiotensin- converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J 1999; 13(Apr): 723-726.
35. Lieberman J, Sastre A. Serum angiotensin-converting enzyme: elevations in diabetes mellitus. Ann Intern Med 1980; 93(6): 825-826.
36. Silverstein E, Brunswick J, Rao TK, Friedland J. Increased serum angiotensinconverting enzyme in chronic renal disease. Nephron 1984; 37(3): 206-210.
37. Gronhagen-Riska C, Kurppa K, Fyhrquist F, Selroos O. Angiotensin-converting enzyme and lysozyme in silicosis and asbestosis. Scand J Respir Dis 1978; 59(4): 228-231.
38. Brice EA, Friedlander W, Bateman ED, Kirsch RE. Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD. Chest 1995; 107(3): 706-710.
39. Ainslie GM, Benatar SR. Serum angiotensin converting enzyme in sarcoidosis: sensitivity and specificity in diagnosis: correlations with disease activity, duration, extra-thoracic involvement, radiographic type and therapy. Q J Med 1985; 55(218): 253-270.
40. Lieberman J, Bell DS. Serum angiotensin-converting enzyme as a marker for the chronic fatigue-immune dysfunction syndrome: a comparison to serum angiotensin-converting enzyme in sarcoidosis. Am J Med 1993; 95(4): 407-412.
41. Brent GA, Hershman JM, Reed AW, Sastre A, Lieberman J. Serum angiotensin- converting enzyme in severe nonthyroidal illnesses associated with low serum thyroxine concentration. Ann Intern Med 1984; 100(5): 680-683.
42. Silverstein E, Schussler GC, Friedland J. Elevated serum angiotensin-converting enzyme in hyperthyroidism. Am J Med 1983; 75(2): 233-236.
43. Davies SF, Rohrbach MS, Thelen V, Kuritsky J, Gruninger R, Simpson ML, et al. Elevated serum angiotensin-converting enzyme (SACE) activity in acute pulmonary histoplasmosis. Chest 1984; 85(3): 307-310.
44. Lieberman J, Rea TH. Serum angiotensin-converting enzyme in leprosy and coccidioidomycosis. Ann Intern Med 1977; 87(4): 423-425.
45. Lieberman J, Beutler E. Elevation of serum angiotensin-converting enzyme in Gaucher’s disease. N Engl J Med 1976; 294(26): 1442-1444.
46. Gupta SK, Chakraborty M, Mitra K. Serum angiotensin converting enzyme in respiratory diseases. Indian J Chest Dis Allied Sci 1992; 34(1): 19-24.
47. Silverstein E, Fierst SM, Simon MR, Weinstock JV, Friedland J. Angiotensinconverting enzyme in Crohn’s disease and ulcerative colitis. Am J Clin Pathol 1981; 75(2): 175-178.
48. Bosi A, Borsotti M, Ghelli P, Tozzi P, Bellesi G, Rossi FP. Serum angiotensin-I-converting enzyme and lysozyme levels in untreated and unsplenectomized patients with Hodgkin’s disease. Acta Haematol 1984; 71(5): 329-333.
49. Romer FK, Emmertsen K. Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiplemyeloma. Br J Cancer 1980; 42(2): 314-318.
50. Takada K, Ina Y, Noda M, Sato T, Yamamoto M, Morishita M. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J Clin Epidemiol 1993; 46(4): 359-366.
51. Lieberman J, Schleissner LA, Nosal A, Sastre A, Mishkin FS. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, gallium-67 scans, chest roentgenograms, and pulmonary function. Chest 1983; 84(5): 522-528.
52. Allen R, Mendelsohn FA, Csicsmann J, Weller RF, Hurley TH, Doyle AE. A clinical evaluation of serum angiotensin converting enzyme in sarcoidosis. Aust N Z J Med 1980; 10(5): 496-501.
53. Silverstein E, Friedland J, Lyons HA. Serum angiotensin converting enzyme in sarcoidosis: clinical significance. Isr J Med Sci 1977; 13(10): 1001-1006.
54. Ziegenhagen MW, Rothe ME, Schlaak M, Muller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003; 21(3): 407-413.
55. Weaver LJ, Solliday NH, Celic L, Cugell D. Serial observations of angiotensin- converting enzyme and pulmonary function in sarcoidosis. Arch Intern Med 1981; 141(7): 931-934.
56. DeRemee RA, Rohrbach MS. Serum angiotensin-converting enzyme activity in evaluating the clinical courseof sarcoidosis. Ann Intern Med 1980; 92(3): 361-365.
57. Gronhagen-Riska C, Selroos O. Angiotensin converting enzyme. IV. Changes in serum activity and in lysozyme concentrations as indicators of the course of untreated sarcoidosis. Scand J Respir Dis 1979; 60(6): 337-344.
58. Lawrence EC, Teague RB, Gottlieb MS, Jhingran SG, Lieberman J. Serial changes in markers of disease activity with corticosteroid treatment in sarcoidosis. Am J Med 1983; 74: 747-756.
59. Baughman RP, Fernandez M, Bosken CH, Mantil J, Hurtubise P. Comparison of gallium-67 scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis. Predicting response to therapy. Am Rev Respir Dis 1984; 129: 676-681.
60. Gronhagen-Riska C, Selroos O, Niemisto M. Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respir Dis 1980; 61(2): 113-122.
61. Baughman RP, Ploysongsang Y, Roberts RD, Srivastava L. Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis 1983; 128: 631-633.
62. Rothkrantz-Kos S, Dieijen-Visser MP, Mulder PG, Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003; 49(9): 1510-1517.
63. Vita JB, Anderson JA, Hulem CD, Leopold IH. Angiotensin-converting enzyme activity in ocular fluids. Invest Ophthalmol Vis Sci 1981; 20(2): 255-257.
64. Immonen I, Friberg K, Sorsila R, Fyhrquist F. Concentration of angiotensinconverting enzyme in tears of patients with sarcoidosis. Acta Ophthalmol (Copenh) 1987; 65(1): 27-29.
65. Sharma OP, Vita JB. Determination of angiotensin-converting enzyme activity in tears. A noninvasive test for evaluation of ocular sarcoidosis. Arch Ophthalmol 1983; 101(4): 559-561.
66. Oksanen V, Fyhrquist F, Somer H, Gronhagen-Riska C. Angiotensin converting enzyme in cerebrospinal fluid: a new assay. Neurology 1985; 35(8): 1220-1223.
67. Lantz I, Nyberg F, Terenius L. Molecular heterogeneity of angiotensin converting enzyme in human cerebrospinal fluid. Biochem Int 1991; 23(5): 941-948.
68. Wahlbeck K, Ahokas A, Nikkila H, Miettinen K, Rimon R. Cerebrospinal fluid angiotensin-converting enzyme (ACE) correlates with length of illness in schizophrenia. Schizophr Res 2000; 41(2): 335-340.
69. Wahlbeck K, Ahokas A, Miettinen K, Nikkila H, Rimon R. Higher cerebrospinal fluid angiotensin-converting enzyme levels in neuroleptic-treated than in drug-free patients with schizophrenia. Schizophr Bull 1998; 24(3): 391-397.
70. Tahmoush AJ, Amir MS, Connor WW, Farry JK, Didato S, Ulhoa-Cintra A, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19(3): 191-197.
71. Jones DB, Mitchell D, Horn DB, Edwards CR. Cerebrospinal fluid angiotensin converting enzyme levels in the diagnosis of neurosarcoidosis. Scott Med J 1991; 36(5): 144-145.
72. Myrvik QN, Leake FS, Farriss B. Lysozyme content of alveolar and peritoneal macrophages from the rabbit. J Immunol 1961; 86: 133-136.
73. Myrvik QN. Serum and tissue lysozyme levels associated Mwith granulomatous reaction. Tuberculol Thorac Dis 1960; 18: 91-94.
74. Perillie PE, Finch SC. Lysozyme in leukemia. Med Clin North Am 1973; 57(2): 395-407.
75. Bjermer L, Back O, Roos G, Thunell M. Mast cells and lysozyme positive macrophages in bronchoalveolar lavage from patients with sarcoidosis. Valuable prognostic and activity marking parameters of disease? Acta Med Scand 1986; 220(2): 161-166.
76. Klockars M, Selroos O. Immunohistochemical demonstration of lysozyme in the lymph nodes and Kveim reaction papules in sarcoidosis. Acta Pathol Microbiol Scand [A] 1977; 85A(2): 169-173.
77. Tomita H, Sato S, Matsuda R, Sugiura Y, Kawaguchi H, Niimi T, et al. Serum lysozyme levels and clinical features of sarcoidosis. Lung 1999; 177(3): 161-167.
78. Koivunen E, Gronhagen-Riska C, Klockars M, Selroos O. Blood monocytes and serum and bone marrow lysozyme in sarcoidosis. Acta Med Scand 1981; 210(1-2): 107-110.
79. Baarsma GS, La Hey E, Glasius E, de Vries J, Kijlstra A. The predictive value of serum angiotensin converting enzyme and lysozyme levels in the diagnosis of ocular sarcoidosis. Am J Ophthalmol 1987; 104(3): 211-217.
80. Pascual RS, Gee JB, Finch SC. Usefulness of serum lysozyme measurement in diagnosis and evaluation of sarcoidosis. NEngl JMed 1973; 289(20): 1074-1076.
81. Prior C, Barbee RA, Evans PM, Townsend PJ, Primett ZS, Fyhrquist F, et al. Lavage versus serum measurements of lysozyme, angiotensin converting enzyme and other inflammatory markers in pulmonary sarcoidosis. Eur Respir J 1990; 3(10): 1146-1154.
82. Klockars M, Pettersson T, Weber TH, Froseth B, Selroos O. Angiotensin-converting enzyme, lysozyme, beta-2-microglobulin and adenosine deaminase in sarcoidosis. Arch Monaldi 1984; 39(5-6): 345-356.
83. Romer FK, Ahlbom G, Jensen JU. Relationship between angiotensin-converting enzyme and lysozyme in sarcoidosis. Eur J Respir Dis 1982; 63(4): 330-336.
84. Gronhagen-Riska C. Angiotensin-converting enzyme. I. Activity and correlation with serum lysozyme in sarcoidosis, other chest or lymph node diseases and healthy persons. Scand J Respir Dis 1979; 60(2): 83-93.
85. Pietinalho A, Ohmichi M, Hiraga Y, Lofroos AB, Selroos O. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis 1996; 13: 159-166.
86. Turton CW, Grundy E, Firth G, Mitchell D, Rigden BG, Turner-Warwick M. Value of measuring serum angiotensin I converting enzyme and serum lysozyme in the management of sarcoidosis. Thorax 1979; 34(1): 57-62.
87. Goldstein RA, Israel HL. An assessment of serum protein electrophoresis in sarcoidosis. Am J Med Sci 1968; 256: 306-313.
88. Goldstein RA, Israel HL, Becker KL, Moore CF. The infrequency of hypercalcemia in sarcoidosis. Am J Med 1971; 51: 21-30.
89. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager HJ, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889.
90. Rizzato G, Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. Sarcoidosis 1996; 13: 167-172.
91. Ponce C, Gujral JS. Renal failure and hypercalcemia as initial manifestations of extrapulmonary sarcoidosis. South Med J 2004; 97(6): 590-592.
92. Ohashi N, Yonemura K, Hirano M, Takahashi S, Kato A, Fujigaki Y, et al. A patient with sarcoidosis presenting with acute renal failure: implication for granulomatous interstitial nephritis and hypercalcemia. Intern Med 2002; 41(12): 1171-1174.
93. Bear RA, Handelsman S, Lang A, Cattran D, Wilson D, Johnson M, et al. Clinical and pathological features of six cases of sarcoidosis presenting with renal failure. Can Med Assoc J 1979; 121(10): 1367-1371.
94. Rikitake Y, Kinoshita Y, Kotani Y, Kawanami C, Asahara M, Matsushima Y, et al. Sarcoidosis with hypercalcemia-successful treatment of renal insufficiency and renal calcification with prednisolone. Intern Med 1994; 33(4): 222-225.
95. Adams JS. Hypercalcemia and hypercalcuria. Semin Resp Med 1992; 13: 402-410.
96. Eastwood M. Vitamins and trace elements. In: Warrell DA, Cox TM, Firth JD, Benz EJ Jr, eds. Oxford textbook of medicine. New York: Oxford University Press, 2003: 1044-1053.
97. Mason RS, Frankel T, Chan YL, Lissner D, Solomon P. Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med 1984; 100: 59-61.
98. Barbour GL, Coburn JW, Slatopolsky E, et al. Hypercalcemia in an anephric patient with sarcoidosis: evidence of extrarenal generation of 1,25 dihydroxyvitamin D. N Engl J Med 1981; 305: 440-443.
99. Cadranel JL, Garabedian M, Milleron B, Guillozzo H, Valeyre D, Paillard F, et al. Vitamin D metabolism by alveolar immune cells in tuberculosis: correlation with calcium metabolism and clinical manifestations. Eur Respir J 1994; 7(6): 1103-1110.
100. Yonemura K, Ohtake T, Matsushima H, Fujigaki Y, Hishida A. High ratio of 1,25-dihydroxyvitamin D3 to parathyroid hormone in serum of tuberculous patients with end-stage renal disease. Clin Nephrol 2004; 62(3): 202-207.
101. Lawn SD, Macallan DC. Hypercalcemia: a manifestation of immune reconstitution complicating tuberculosis in an HIV-infected person. Clin Infect Dis 2004; 38(1): 154-155.
102. Lee CT, Hung KH, Lee CH, Eng HL, Chen JB. Chronic hypercalcemia as the presenting feature of tuberculous peritonitis in a hemodialysis patient. Am J Nephrol 2002; 22(5-6): 555-559.
103. Chan TY, Chan CH, Shek CC. The prevalence of hypercalcaemia in pulmonary and miliary tuberculosis-a longitudinal study. Singapore Med J 1994; 35(6): 613-615.
104. Playford EG, Bansal AS, Looke DF, Whitby M, Hogan PG. Hypercalcaemia and elevated 1,25(OH)(2)D(3) levels associated with disseminated Mycobacterium avium infection in AIDS. J Infect 2001; 42(2): 157-158.
105. Caldwell JW, Arsura EL, Kilgore WB, Reddy CM, Johnson RH. Hypercalcemia in patients with disseminated coccidioidomycosis. Am J Med Sci 2004; 327(1): 15-18.
106. Murray JJ, Heim CR. Hypercalcemia in disseminated histoplasmosis. Aggravation by vitamin D. Am J Med 1985; 78(5): 881-884.
107. Rottoli P, Muscettola M, Grasso G, Perari MG, Vagliasindi M. Imparied interferon- gamma production by peripheral blood mononuclear cells and effects of calcitriol in pulmonary sarcoidosis. Sarcoidosis 1993; 10(2): 108-114.
108. Robinson BW, McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985; 75(May): 1488-1495.
109. Hamada K, Nagai S, Tsutsumi T, Izumi T. Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J 1998; 11(5): 1015-1020.
110. Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med 1989; 111(5): 437-438.
111. Adams JS, Sharma OP, Diz M. Ketoconazole decreases the serum 1,25 dihydroxyvitamin D and calcium concentration in sarcoidosis associated hypercalcemia. J Clin Endocrinol Metab 1990; 70: 1090-1095.
112. Subramanian P, Chinthalapalli H, Krishnan M, Tarlo SM, Lobbedez T, Pineda ME, et al. Pregnancy and sarcoidosis: an insight into the pathogenesis of hypercalciuria. Chest 2004; 126(3): 995-998.
113. Lang CC, McEwan SR, Ng AK. Co-existing hyperparathyroidism and sarcoidosis presenting with hypercalcaemia-a diagnostic challenge. Scott Med J 1989; 34(4): 503-504.
114. Ghose RR, Woodhead JS, Brown RC. Incomplete suppression of parathyroid hormone activity in sarcoidosis presenting with hypercalcaemia. Postgrad Med J 1983; 59(695): 572-574.
115. Dawidson I, Jameson S. Sarcoidosis with hypercalcemia, reversible uremia and hyperparathyroidism. Scand J Urol Nephrol 1972; 6(3): 308-311.
116. Robinson RG, Kerwin DM, Tsou E. Parathyroid adenoma with coexistent sarcoid granulomas. A hypercalcemic patient. Arch Intern Med 1980; 140(11): 1547-1548.
117. Nabriski D, Bendahan J, Shapiro MS, Freund U, Lidor C. Sarcoidosis masquerading as a parathyroid adenoma. Head Neck 1992; 14(5): 384-386.
118. DeRemee RA, Lufkin EG, Rohrbach MS. Serum angiotensin-converting enzyme activity. Its use in the evaluation and management of hypercalcemia associated with sarcoidosis. Arch Intern Med 1985; 145(4): 677-679.
119. Lufkin EG, DeRemee RA, Rohrbach MS. The predictive value of serum angiotensin-converting enzyme activity in the differential diagnosis of hypercalcemia. Mayo Clin Proc 1983; 58(7): 447-451.
120. Schweisfurth H, Schmidt M, Reinhart E, Brugger E. Kininase I and II activities in serumof patients with lung diseases. Adv ExpMed Biol 1986; 198(Pt B): 439-442.
121. Almenoff J, Teirstein AS, Thornton JC, Orlowski M. Identification of a thermolysin- like metalloendopeptidase in serum: activity in normal subjects and in patients with sarcoidosis. J Lab Clin Med 1984; 103(3): 420-431.
122. Almenoff J, Skovron ML, Teirstein AS. Thermolysin-like serum metalloendopeptidase. A new marker for active sarcoidosis that complements serum angiotensin-converting enzyme. Ann N Y Acad Sci 1986; 465: 738-743.
123. Almenoff J, Teirstein AS. Clinical significance of serum thermolysin-like metalloendopeptidase and its relationship to serum angiotensin converting enzyme in sarcoidosis. Am J Med 1987; 82(1): 33-38.
124. Lacronique J, Auzeby A, Valeyre D, Traore BM, Barbosa ML, Soler P, et al. Urinary neopterin in pulmonary sarcoidosis. Relationship to clinical and biologic assessment of the disease. Am Rev Respir Dis 1989; 139(6): 1474-1478.
125. Hoffmann G, Rieder J, Smolny M, Seibel M, Wirleitner B, Fuchs D, et al. Neopterin-induced expression of intercellular adhesion molecule-1 (ICAM-1) in type II-like alveolar epithelial cells. Clin Exp Immunol 1999; 118(3): 435-440.
126. Homolka J, Lorenz J, Zuchold HD, Muller-Quernheim J. Evaluation of soluble CD 14 and neopterin as serum parameters of the inflammatory activity of pulmonary sarcoidosis. Clin Investig 1992; 70(10): 909-916.
127. Eklund A, Blaschke E. Elevated serum neopterin levels in sarcoidosis. Lung 1986; 164(6): 325-332.
128. Prior C, Frank A, Fuchs D, Hausen A, Judmaier G, Reibnegger G, et al. Urinary neopterin excretion in pulmonary sarcoidosis: correlation to clinical course of the disease. Clin Chim Acta 1988; 177(3): 211-220.
129. Blaschke E, Eklund A, Persson U. Relationship between serum neopterin and lymphocytic alveolitis in sarcoidosis. Sarcoidosis 1988; 5(1): 25-30.
130. Planck A, Eklund A, Grunewald J. Markers of activity in clinically recovered human leukocyte antigen-DR17-positive sarcoidosis patients. Eur Respir J 2003; 21(1): 52-57.
131. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Muller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156(5): 1586-1592.
132. Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981; 305: 429-432.
133. Pinkston P, Bitterman PB, Crystal RG. Spontaneous release of interleukin-2 by lung lymphocytes in active pulmonary sarcoidosis. N Engl J Med 1983; 308: 793-800.
134. Mehta R, Shah G, Adler W, Kittur D. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients. Clin Transplant 2004; 18(Suppl 12): 67-71.
135. Lawrence EC, Holland VA, Young JB, Windsor NT, Brousseau KP, Noon GP, et al. Dynamic changes in soluble interleukin-2 receptor levels after lung or heart-lung transplantation. Am Rev Respir Dis 1989; 140(3): 789-796.
136. McNally CM, Luckhurst E, Penny R. Cell free serum interleukin-2 receptor levels after heart transplantation. J Heart Lung Transplant 1991; 10(5 Pt 1): 769-774.
137. Lawrence EC, Brousseau KP, Berger MB, Kurman CC, Marcon L, Nelson DL. Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Respir Dis 1988; 137(4): 759-764.
138. Semenzato G, Cipriani A, Trentin L, Zambello R, Masciarelli M, Vinante F, et al. High serum levels of soluble interleukin-2 receptors in sarcoidosis. Sarcoidosis 1987; 4(1): 25-27.
139. Tsutsumi T, Nagai S, Imai K, Setoyama Y, Uchiyama T, Izumi T. Soluble interleukin-2 receptor in blood from patients with sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis 1994; 11(2): 102-109.
140. Keicho N, Kitamura K, Takaku F, Yotsumoto H. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest 1990; 98(5): 1125-1129.
141. Harada T, Amano T, Takahashi A, Furuya J, Yamaguchi E, Kaji M, et al. Necrotizing sarcoid granulomatosis presenting with elevated serum soluble interleukin-2 receptor levels. Respiration 2002; 69(5): 468-470.
142. Grutters JC, Fellrath JM, Mulder L, Janssen R, van den Bosch JM, Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003; 124(1): 186-195.
143. Pforte A, Brunner A, Gais P, Burger G, Breyer G, Strobel M, et al. Concomitant modulation of serum-soluble interleukin-2 receptor and alveolar macrophage interleukin-2 receptor in sarcoidosis. Am Rev Respir Dis 1993; 147(3): 717-722.
144. Muller-Quernheim J, Pfeifer S, Strausz J, Ferlinz R. Correlation of clinical and immunologic parameters of the inflammatory activity of pulmonary sarcoidosis. Am Rev Respir Dis 1991; 144(6): 1322-1329.
145. Rothkrantz-Kos S, Dieijen-Visser MP, Mulder PG, Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003; 49(9): 1510-1517.
146. Bernier GM, Fanger MW. Synthesis of 2-microglobulin by stimulated lymphocytes. J Immunol 1972; 109(2): 407-409.
147. Child JA, Spati B, Illingworth S, Barnard D, Corbett S, Simmons AV, et al. Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients. CANCER 1980; 45(2): 318-326.
148. Zissis M, Afroudakis A, Galanopoulos G, Palermos L, Boura X, Michopoulos S, et al. B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease? Am J Gastroenterol 2001; 96(7): 2177-2183.
149. Mornex JF, Revillard JP, Vincent C, Deteix P, Brune J. Elevated serum beta 2- microglobulin levels and C1q-binding immune complexes in sarcoidosis. Biomedicine 1979; 31(7): 210-213.
150. Selroos O, Klockars M. Relation between clinical stage of sarcoidosis and serum values of angiotensin converting enzyme and beta2-microglobulin. Sarcoidosis 1987; 4(1): 13-17.
151. Parrish RW, Williams JD, Davies BH. Serum beta-2-microglobulin and angiotensin- converting enzyme activity in sarcoidosis. Thorax 1982; 37(12): 936-940.
152. Ward K, O’Connors C, Odlun C, Fitzgerald FX. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax 1989; 44: 6-12.
153. Keogh BA, Hunninghake GW, Line BR, Crystal RG. The alveolitis of pulmonary sarcoidosis: evaluation of natural history and alveolitis-dependant changes in lung function. Am Rev Respir Dis 1983; 128: 256-265.
154. Al Shammary FJ. Adenosine deaminase activity in serum and pleural effusions of tuberculous and non-tuberculous patients. Biochem Mol Biol Int 1997; 43(4): 763-779.
155. Albera C, Mabritto I, Ghio P, Solidoro P, Marchetti L, Pozzi E. Adenosine deaminase activity and fibronectin levels in bronchoalveolar lavage fluid in sarcoidosis and tuberculosis. Sarcoidosis 1993; 10(1): 18-25.
156. Taylor A. Serum adenosine deaminase activity is increased in sarcoidosis. Clin Chem 1984; 30(3): 499-500.
157. Mana J, Orts J, Fuentes J, Badrinas F. Serum adenosine deaminase assay in sarcoidosis has little clinical usefulness. Clin Chem 1986; 32(7): 1429-1430.
158. Klockars M, Pettersson T, Weber TH, Froseth B, Selroos O. Angiotensin-converting enzyme, lysozyme, beta-2-microglobulin and adenosine deaminase in sarcoidosis. Arch Monaldi 1984; 39(5-6): 345-356.
159. Lin YH, Haslam PL, Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. Thorax 1985; 40: 501-507.
160. Drent M, Jacobs JA, de Vries J, Lamers RJ, Liem IH, Wouters EF. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J 1999; 13(6): 1338-1344.
161. Baughman RP, Keeton D, Lower EE. Relationship between interleukin-8 and neutrophils in the BAL fluid of sarcoidosis. Sarcoidosis 1994; 11: S217-S220.
162. Silverstein E, Lockerman Z, Friedland J. Serum and lymph-node collagenase in sarcoidosis. Comparison with angiotensin-converting enzyme. Am J Clin Pathol 1978; 70(3): 348-351.
163. O’Connor C, Odlum C, Van Breda A, Power C, Fitz Gerald MX. Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis. Thorax 1988; 43(5): 393-400.
164. Ward K, O’Connor CM, Odlum C, Power C, Fitz Gerald MX. Pulmonary disease progress in sarcoid patients with and without bronchoalveolar lavage collagenase. Am Rev Respir Dis 1990; 142(3): 636-641.
165. Idell S, Kucich U, Fein A, Kueppers F, James HL, Walsh PN, et al. Neutrophil elastase-releasing factors in bronchoalveolar lavage from patients with adult respiratory distress syndrome. Am Rev Respir Dis 1985; 132(5): 1098-1105.
166. Baughman RP, Gunther KL, Rashkin MC, Keeton DA, Pattishall EN. Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. Am J Respir Crit Care Med 1996; 154: 76-81.
167. Smith SF, Guz A, Burton GH, Heaton R, Cooke NT, Tetley TD. The elastase: anti-elastase profile in lung lavage from sarcoidosis patients. Sarcoidosis 1988; 5(1): 31-37.
168. Peros-Golubicic T, Ivicevic A, Bekic A, Alilovic M, Tekavec-Trkanjec J, Smojver-Jezek S. Lung lavage neutrophils, neutrophil elastase and albumin in the prognosis of pulmonary sarcoidosis. Coll Antropol 2001; 25(1): 349-355.
169. Hind CR, Latchman YE, Brostoff J. Circulating human leucocyte elastase levels in patients with pulmonary sarcoidosis. Sarcoidosis 1988; 5(1): 38-42.
170. Peros-Golubicic T. Prognostic value of plasma neutrophil elastase levels in pulmonary sarcoidosis. Acta Med Croatica 1993; 47(1): 15-18.
171. Blaschke E, Eklund A, Hernbrand R. Extracellular matrix components in bronchoalveolar lavage fluid in sarcoidosis and their relationship to signs of alveolitis. Am Rev Respir Dis 1990; 141(4 Pt 1): 1020-1025.
172. O’Connor C, Ward K, Van Breda A, McIlgorm A, Fitz Gerald MX. Type 3 procollagen peptide in bronchoalveolar lavage fluid. Poor indicator of course and prognosis in sarcoidosis. Chest 1989; 96(2): 339-344.
173. Straub JP, van Kamp GJ, van Maarsseveen TC, Stam J. Biochemical parameters in BAL of sarcoisosis. Sarcoidosis 1995; 12(1): 51-57.
174. Luisetti M, Bulgheroni A, Bacchella L, Pasturenzi L, Aprile C. Elevated serum procollagen III aminopeptide levels in sarcoidosis. Chest 1990; 98(6): 1414-1420.
175. Milman N, Kristensen MS, Bentsen K, Grode G, Frederiksen J. Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. Sarcoidosis 1995; 12(1): 38-41.
176. Planck A, Eklund A, Grunewald J. Inflammatory BAL-fluid and serum parameters in HLA DR17 positive versus DR17 negative patients with pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18(1): 64-69.
177. Eklund AG, Sigurdardottir O, Ohrn M. Vitronectin and its relationship to other extracellular matrix components in bronchoalveolar lavage fluid in sarcoidosis. Am Rev Respir Dis 1992; 145(3): 646-650.
178. Pohl WR, Conlan MG, Thompson AB, Ertl RF, Romberger DJ, Mosher DF, et al. Vitronectin in bronchoalveolar lavage fluid is increased in patients with interstitial lung disease. Am Rev Respir Dis 1991; 143(6): 1369-1375.
179. Bjermer L, Eklund A, Blaschke E. Bronchoalveolar lavage fibronectin in patients with sarcoidosis: correlation to hyaluronan and disease activity. Eur Respir J 1991; 4(8): 965-971.
180. Hallgren R, Eklund A, Engstrom-Laurent A, Schmekel B. Hyaluronate in bronchoalveolar lavage fluid: a new marker in sarcoidosis reflecting pulmonary disease. Br Med J (Clin Res Ed) 1985; 290(6484): 1778-1781.
181. Bjermer L, Engstrom-Laurent A, Thunell M, Hallgren R. Hyaluronic acid in bronchoalveolar lavage fluid in patients with sarcoidosis: relationship to lavage mast cells. Thorax 1987; 42(12): 933-938.
182. Barth WF. Office evaluation of the patient with musculoskeletal complaints. Am J Med 1997; 102(1A): 3S-10S.
183. Shorr AF, Murphy FT, Gilliland WR, Hnatiuk W. Osseous disease in patients with pulmonary sarcoidosis and musculoskeletal symptoms. Respir Med 2000; 94(3): 228-232.
184. Lindsley CB, Petty RE. Overview and report on international registry of sarcoid arthritis in childhood. Curr Rheumatol Rep 2000; 2(4): 343-348.
185. Pattishall EN, Strope GL, Spinola SM, Denny FW. Childhood sarcoidosis. J Pediatr 1986; 108: 169-177.
186. Hind CR, Flint KC, Hudspith BN, Felmingham D, Brostoff J, Johnson NM. Serum C-reactive protein concentrations in patients with pulmonary sarcoidosis. Thorax 1987; 42(5): 332-335.
187. Peros-Golubicic T. Serum C-reactive protein measurement in the detection of intercurrent infection in patients with sarcoidosis. Acta Med Croatica 1995; 49(1): 1-3.
188. Drent M, Wirnsberger RM, de Vries J, Dieijen-Visser MP, Wouters EF, Schols AM. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999; 13(4): 718-722.
189. Salazar A, Mana J, Fiol C, Hurtado I, Argimon JM, Pujol R, et al. Influence of serum amyloid A on the decrease of high density lipoprotein-cholesterol in active sarcoidosis. Atherosclerosis 2000; 152(2): 497-502.
190. Salazar A, Pinto X, Mana J. Serum amyloid A and high-density lipoprotein cholesterol: serum markers of inflammation in sarcoidosis and other systemic disorders. Eur J Clin Invest 2001; 31(12): 1070-1077.
191. Szechinski J, Skoczynska A, Smolik R, Zdrojewicz Z, Behal FJ. Serum angiotensin- converting enzyme levels in patients with silicosis. J Toxicol Environ Health 1986; 17(1): 73-79.
192. Newman LS, Orton R, Kreiss K. Serum angiotensin converting enzyme activity in chronic beryllium disease. Am Rev Respir Dis 1992; 146(1): 39-42.
193. O’Connor C, Odlum C, Van Breda A, Power C, Fitz Gerald MX. Collagenase and fibronectin in branchoalveolar lavage fluid in patients with sarcoidosis. Therax 1988; 43(5): 393-400.